Wong Stephen, Rickard Mary, Earls Peter, Arnold Lauren, Bako Barnabas, Field Andrew S
Department of Anatomical Pathology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
Consultant Radiologist BreastScreen NSW and Faculty of Health Sciences University of Sydney, Sydney, New South Wales, Australia.
Acta Cytol. 2019;63(4):280-291. doi: 10.1159/000500191. Epub 2019 May 20.
To review the performance and utility of the International Academy of Cytology (IAC) Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy (FNAB) Cytology five category stratification and evaluate the impact of rapid onsite evaluation (ROSE).
A retrospective analysis of breast FNAB cytology cases with matched histopathological results at a single institution over a 32 months period using a structured reporting system with 5 diagnostic categories ("inadequate/insufficient," "benign," "atypical," "suspicious of malignancy" and "malignant") closely paralleling the proposed IAC System.
Of 2,696 breast FNAB cases, there were 579 with matched histopathology and 456 of these had ROSE. ROSE decreased the number in the "insufficient" category (17.1% without ROSE to 4.0% with ROSE) and increased the number in the "malignant" (17.9 to 39.0%) with a lesser impact on the "atypical," "benign" and "suspicious of malignancy" categories. The performance data showed a positive predictive value of 96.4%, negative predictive value of 97.6%, and a risk of malignancy of a FNAB categorized as "insufficient" to be 2.6%, "benign" 1.7%, "atypical" 15.7%, "suspicious of malignancy" 84.6%, and "malignant" 99.5%.
Breast FNAB is an accurate test enabling effective diagnosis of breast lesions. ROSE improved the performance by decreasing the proportion of "insufficient" and "atypical" and increasing the "suspicious of malignancy" and "malignant" diagnoses and enabling immediate triage for further biopsy where necessary.
回顾国际细胞学会(IAC)横滨系统在乳腺细针穿刺活检(FNAB)细胞学五类分层报告中的表现及实用性,并评估快速现场评估(ROSE)的影响。
对某单一机构32个月期间乳腺FNAB细胞学病例进行回顾性分析,这些病例具有匹配的组织病理学结果,采用与拟议的IAC系统紧密平行的包含5个诊断类别的结构化报告系统(“不充分/不足”、“良性”、“非典型”、“可疑恶性”和“恶性”)。
在2696例乳腺FNAB病例中,有579例具有匹配的组织病理学结果,其中456例进行了ROSE。ROSE减少了“不足”类别的数量(无ROSE时为17.1%,有ROSE时为4.0%),增加了“恶性”类别的数量(从17.9%增至39.0%),对“非典型”、“良性”和“可疑恶性”类别的影响较小。性能数据显示,阳性预测值为96.4%,阴性预测值为97.6%,分类为“不足”的FNAB恶性风险为2.6%,“良性”为1.7%,“非典型”为15.7%,“可疑恶性”为84.6%,“恶性”为99.5%。
乳腺FNAB是一种准确的检测方法,能够有效诊断乳腺病变。ROSE通过减少“不足”和“非典型”的比例,增加“可疑恶性”和“恶性”诊断的比例,并在必要时能够立即进行分流以便进一步活检,从而提高了性能。